Arcadia Biosciences, Inc. (RKDA) Financial Statements
Industry: Crude Petroleum & Natural Gas
In fiscal 2025, Arcadia Biosciences reported revenue of $4.9M, down 3.7% from $5.0M the year before. Net income was -$2.3M (a -48.1% net margin), or -$1.71 per diluted share. Gross margin was 36.2% and operating margin was -51.5%. Operating activities generated -$4.7M of cash, leaving -$4.7M of free cash flow. At fiscal year end, Arcadia Biosciences held $6.5M in total assets against $2.4M in total liabilities, including $259,000 of cash and equivalents.
Open the full interactive Arcadia Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Arcadia Biosciences Key Stats
| Share Price | $0.21 |
|---|---|
| Market Cap | $622,451 |
| Revenue YoY Growth | -3.7% |
| 52-Week Range | $0.21 – $5.48 |
| Shares Outstanding | 3.0 million (basic, 2026 Q2) |
Arcadia Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.0M | $6.8M | $10.0M | $5.3M | $5.0M | $4.9M |
| Cost of Goods Sold | $5.2M | $8.7M | $9.8M | $3.3M | $3.0M | $3.1M |
| Gross Profit | $2.8M | -$1.9M | $154,000 | $2.0M | $2.1M | $1.8M |
| Operating Income | -$12.8M | -$35.5M | -$18.8M | -$13.9M | -$3.6M | -$2.5M |
| Pre-Tax Income | -$6.2M | -$16.1M | -$15.6M | -$13.2M | -$4.3M | -$2.3M |
| Income Tax | -$124,000 | $2,000 | $14,000 | $8,000 | $8,000 | $8,000 |
| Net Income | -$4.7M | -$14.7M | -$15.4M | -$14.0M | -$7.0M | -$2.3M |
| Diluted EPS | -$18.80 | -$27.60 | -$25.65 | -$11.30 | -$5.17 | -$1.71 |
Arcadia Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.3M | $901,000 | $1.1M | $1.4M |
| Net Income | $856,000 | -$1.3M | -$4.4M | -$6.3M |
| Diluted EPS | $0.62 | -$0.98 | -$2.11 | -$2.09 |
Arcadia Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.0M | $28.7M | $20.6M | $6.5M | $4.2M | $259,000 |
| Current Assets | $31.7M | $35.4M | $25.4M | $15.0M | $9.2M | $6.4M |
| Total Assets | $47.3M | $43.9M | $28.9M | $19.7M | $13.5M | $6.5M |
| Current Liabilities | $6.3M | $5.0M | $4.2M | $3.6M | $2.6M | $2.1M |
| Total Long-Term Debt | $2.1M | — | — | — | — | — |
| Total Liabilities | $18.8M | $12.7M | $8.0M | $7.0M | $7.3M | $2.4M |
| Shareholders' Equity | $27.7M | $31.1M | $21.0M | $12.8M | $6.2M | $4.1M |
Arcadia Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$30.2M | -$25.9M | -$14.0M | -$15.3M | -$9.6M | -$4.7M |
| Cash From Investing | $17.3M | $16.6M | $1.4M | -$4.3M | $7.3M | $750,000 |
| Cash From Financing | $20.6M | $21.9M | $4.5M | $5.5M | $9,000 | $6,000 |
| Free Cash Flow | -$32.6M | -$26.9M | -$14.1M | -$15.3M | -$9.6M | -$4.7M |
Figures from Arcadia Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Arcadia Biosciences financials page for every line item.
Arcadia Biosciences Company Profile
| Ticker | RKDA |
|---|---|
| Exchange | Nasdaq |
| Industry | Crude Petroleum & Natural Gas |
| Headquarters | Dallas, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001469443 |
Frequently Asked Questions
What was Arcadia Biosciences' revenue in fiscal 2025?
Arcadia Biosciences (RKDA) reported revenue of $4.9M for fiscal 2025.
What is Arcadia Biosciences' annual revenue history?
Arcadia Biosciences' annual revenue by fiscal year: 2020: $8.0M; 2021: $6.8M; 2022: $10.0M; 2023: $5.3M; 2024: $5.0M; 2025: $4.9M.
What was Arcadia Biosciences' net income in fiscal 2025?
Arcadia Biosciences reported net income of -$2.3M for fiscal 2025.
What was Arcadia Biosciences' earnings per share (EPS) in fiscal 2025?
Arcadia Biosciences' diluted EPS was -$1.71 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Arcadia Biosciences generate in fiscal 2025?
Arcadia Biosciences generated -$4.7M of free cash flow in fiscal 2025.
What was Arcadia Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Arcadia Biosciences reported revenue of $1.4M.
How many shares of Arcadia Biosciences are outstanding?
Arcadia Biosciences reported a weighted average of 3.0 million basic shares outstanding in 2026 Q2.
What is Arcadia Biosciences' market cap?
Based on its latest closing price, Arcadia Biosciences (RKDA) has a market capitalization of about $622,451.
When does Arcadia Biosciences' fiscal year end?
Arcadia Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Arcadia Biosciences headquartered?
Arcadia Biosciences lists its business address in Dallas, Texas in its SEC filings.